What is it about?
Specific clinical factors that may be associated with a nonresponse to TNF blockers in patients with psoriasis have not been elucidated. We investigated the non-response rates to all available anti-TNF agents in 110 consecutive psoriatic patients treated with anti-TNF-alpha agents
Featured Image
Why is it important?
Smoking was associated with nonresponse to anti-TNF-a treatment. A significant proportion of non-responders was overweight or obese. Finally, baseline disease severity as assessed by PASI score was higher in the group of non-responders.
Perspectives
Given the considerable impact of targeted therapies on healthcare systems, predictors of therapeutic response to biologics would be of great importance in driving decisions on treatment options, tailoring therapy and reducing toxicity or medical expenses in patients with psoriasis. Biomarkers could help in the future to predict which patients will respond best to a specific drug.
Dr Vito Di Lernia
Arcispedale S. Maria Nuova
Read the Original
This page is a summary of: Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study, Journal of Dermatological Treatment, May 2013, Taylor & Francis,
DOI: 10.3109/09546634.2013.800184.
You can read the full text:
Contributors
The following have contributed to this page
